information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Thursday 26 June 2014

BioVet-PA and BioPhage-PA from Biocontrol Limited

Old post
Sunday, 11 July 2010

BioVet-PA and BioPhage-PA are the same mixture of six bacteriophages specific for Pseudomonas aeruginosa containing 1x10^5 pfu by original titration of each of the 6 therapeutic bacteriophages.

The six bacteriophage strains (which were deposited at the National Collection of Industrial and Marine Bacteria, 23 St Machar Drive, Aberdeen, AB24 3RY, Scotland, UK on 24 June 2003) :


 Reference NCIMB Deposit

1- BC-BP-01 NCIMB 41174
2- BC-BP-02 NCIMB 41175

3-BC-BP-03 NCIMB 41176
4- BC-BP-04 NCIMB 41177
5- BC-BP-05 NCIMB 41178 
6- BC-BP-06 NCIMB 41179

Veterinary Field Trial

A combined preparation of six bacteriophages was named BioVet-PA, and was authorized for trial in dogs with such infection by the Veterinary Medicines Directorate of the United Kingdom in November 2003.

Conduct of the Trial

BioVet-PA was stored at -80° C. Immediately prior to administration, the product was thawed and warmed in the hand 0.2 ml (containing 1x10^5 pfu by original titration of each of the 6 bacteriophages) was administered drop-wise using a sterile 1 ml capacity syringe into the ear. Ear condition and microbiology was assessed at 2 days post-administration.


Human Clinical Trial


This study investigated the efficacy and safety of BioPhage-PA, a mixture of six Pseudomonas aeruginosa bacteriophages of the same types as those tested as BioVet-PA in the veterinary field trial.

BIOPHAGE-PA